Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 245

Sort by

Sort Order Select

Journal Articles

The Effect of Anticoagulant Choice on Venous Thromboembolism Recurrence and Bleeding in Sickle Cell Disease

Vishal K Gupta, MD, Romy Carmen Lawrence, MD BS, Sarah L. Khan, Rachel Strykowski, MD, Brittany Scarpato, MD, Robyn T. Cohen, MD MPH, John Mark Sloan, MD, Elizabeth S Klings, MD

Blood (2019) 134 (Supplement_1): 2272.

https://doi.org/10.1182/blood-2019-122113

Published: 2019

Journal Articles

Impact of Adding Aspirin to Direct Oral Anticoagulant Therapy without an Apparent Indication

Jordan K Schaefer, MD, Yun Li, PhD, Xiaowen Kong, MA, Tina Alexandris-Souphis, RN, Mona A Ali, PharmD, Brian Haymart, RN, MS, Scott Kaatz, DO, MSc, Eva Kline-Rogers, RN, MS, Jay H Kozlowski, MD, Gregory D Krol, Sahana R Shankar, Suman L Sood, MD, James B Froehlich, MD MPH, Geoffrey D Barnes, MD MSc

Blood (2019) 134 (Supplement_1): 787.

https://doi.org/10.1182/blood-2019-122526

Published: 2019

Journal Articles

Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study

Alfonso J Tafur, MD MS, Na Li, PhD, Nathan Clark, PharmD, Sam Schulman, MD PhD FRCPC, Alex Spyropoulos, MD, Joseph A Caprini, MD MS, FACS, RVT, James Douketis, MD

Blood (2019) 134 (Supplement_1): 710.

https://doi.org/10.1182/blood-2019-125292

Published: 2019

Journal Articles

High Rates of Venous and Arterial Thrombotic Events in POEMS Patients: Results from the UK-Based POEMS Registry, Highlighting the Need for Therapeutic Guidelines

Zara Sayar, MD FRCPath, MRCP, Anna Weatherill, Stephen Keddie, Jonathan Sive, MD, Michael P Lunn, Mari Thomas, Shirley D'Sa

Blood (2019) 134 (Supplement_1): 714.

https://doi.org/10.1182/blood-2019-125639

Published: 2019

Journal Articles

Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors

Michiel Coppens, MD, Lizhen Xu, PhD, Roisin Bavalia, MD, Saskia Middeldorp, MD PhD, Peter Verhamme, MD PhD, John W. Eikelboom, MBBS, MSc, FRACP, FRCPA, Mark Crowther, MD, Genmin Lu, Patrick Yue, MD, Pamela B. Conley, PhD, Stuart J. Connolly, MD MSc, FRCPC

Blood (2019) 134 (Supplement_1): 711.

https://doi.org/10.1182/blood-2019-124596

Published: 2019

Journal Articles

Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By Andexanet Alfa and "Work Around" By PCCs

Genmin Lu, Joyce P. Lin, BS, Khanh Bui, BS, John T. Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2019) 134 (Supplement_1): 713.

https://doi.org/10.1182/blood-2019-124864

Published: 2019

Journal Articles

Enhanced VTE Risk Stratification in Ambulatory Patients with Cancer

Joseph R. Shaw, MD, Ranjeeta Mallick, PhD MSc, BSc, Marc Carrier, MD, Anton Ilich, MD, Nigel S. Key, MBChB, FRCP, Philip S. Wells, MDMSc,FRCP

Blood (2019) 134 (Supplement_1): 634.

https://doi.org/10.1182/blood-2019-126306

Published: 2019

Journal Articles

Bleeding Risk in a Cohort of Ambulatory Cancer Patients Receiving Outpatient Prophylactic Anticoagulation for Venous Thrombosis Prevention

Andrew B Wilks, MD MS, Daniel Douce, MD, Steven Ades, MD, Mary Cushman, MD MSc, Neil A. Zakai, MD MSc, Chris E. Holmes, MD PhD

Blood (2019) 134 (Supplement_1): 709.

https://doi.org/10.1182/blood-2019-128831

Published: 2019

Journal Articles

Anticoagulation Challenges in Hematogeriatrics: Effectiveness and Safety of Direct Oral Anticoagulants Vs Vitamin k Antagonist in Elderly with Atrial Fibrillation

Desirée Campoy, MD, Gonzalo Artaza, MD, César A Velasquez, MD, Tania Canals, MD, Erik A Johansson, MD, Katia Flores, MD, Gabriela Bastidas, MD, Silvia Ruiz, MD, Gabriela S Ene, MD PhD, Alessandra Comai, MD, Maricel Subira, MD PhD, Ramón Salinas, MD PhD, Jorge Sierra, MD, Pável E Olivera, MD

Blood (2019) 134 (Supplement_1): 1162.

https://doi.org/10.1182/blood-2019-125150

Published: 2019

Journal Articles

Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms

Kelly L. Schoenbeck, MD, Giselle Salmasi, MD, Miguel Carlos Cerejo, DO, Patricia A. Cornett, MD, Lloyd E. Damon, MD, Aaron C. Logan, MD PhD, Rebecca L. Olin, MD, Andrew D. Leavitt, MD, Catherine C. Smith, MD

Blood (2019) 134 (Supplement_1): 1165.

https://doi.org/10.1182/blood-2019-129705

Published: 2019

Journal Articles

Safety and Efficacy of Apixaban Thromboprophylaxis in Cancer Patients with Metastatic Disease: A Subgroup Analysis of the Avert Trial

William Knoll, BSc, Ranjeeta Mallick, PhD MSc, BSc, Philip S. Wells, MDMSc,FRCP, Marc Carrier, MD

Blood (2019) 134 (Supplement_1): 1140.

https://doi.org/10.1182/blood-2019-128834

Published: 2019

Journal Articles

Incidental Pulmonary Embolism. Analysis of Mayo Clinic Venous Thromboembolism Database

Ewa Wysokinska, MD, Damon E. Houghton, MDMS, Danielle Vlazny, PA-C, Aneel A. Ashrani, MD MS, David A Froehling, MD, David O. Hodge, MS, Lisa Peterson, RN, Robert D. McBane, MD, Waldemar E. Wysokinski, MD PhD, Ana I Casanegra, MD

Blood (2019) 134 (Supplement_1): 1147.

https://doi.org/10.1182/blood-2019-131547

Published: 2019

Journal Articles

The Use of Direct Oral Anticoagulants in Non-Cirrhotic Portal Vein Thrombosis

Leonard Naymagon, MD, Douglas Tremblay, MD, Nicole Zubizarreta, MPH, Erin Moshier, MS, Thomas Schiano, MD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 1154.

https://doi.org/10.1182/blood-2019-124042

Published: 2019

Journal Articles

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban By Andexanet Alfa As Measured By Whole Blood Thromboelastographic Analysis

Siddharth Mehrotra, Debra Hoppensteadt, PhD, Walter Jeske, PhD, Omer Iqbal, MD, Alfonso J Tafur, MD MS, Bruce Lewis, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 1155.

https://doi.org/10.1182/blood-2019-131907

Published: 2019

Journal Articles

Characterizing the Use of Direct Oral Anticoagulants in Children Using the American Thrombosis and Hemostasis Network Dataset (ATHNdataset)

Jennifer G. Davila, MD, Dunlei Cheng, PhD, Leslie J. Raffini, MD, Courtney D. Thornburg, MD, Fernando F. Corrales-Medina, MD

Blood (2019) 134 (Supplement_1): 1156.

https://doi.org/10.1182/blood-2019-128324

Published: 2019

Journal Articles

Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux

Fakiha Siddiqui, Alfonso J Tafur, MD MS, Debra Hoppensteadt, PhD, Jeanine Walenga, PhD, Walter Jeske, PhD, Emily Bontekoe, Ahmed Kouta, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 1158.

https://doi.org/10.1182/blood-2019-127072

Published: 2019

Journal Articles

Safety and Efficacy of Apixaban Versus Enoxaparin/Warfarin in Patients with Extremes of Body Weight: Post-Hoc Analysis of the AMPLIFY Trial

Theodore Lee, MD, Sharon Pan, Wonkyung Byon, Bushra S Ilyas

Blood (2019) 134 (Supplement_1): 1152.

https://doi.org/10.1182/blood-2019-121542

Published: 2019

Journal Articles

Modified Anti-FXa Assays for Measuring the Residual Activity of Apixaban and Rivaroxaban in Andexanet Alfa-Containing Samples on the ACL TOP Family ® Coagulation Analyzers

Anuja Khan, PhD, Krisjela Shishko, BS, Sam Arcidiacono, BS, Khanh Bui, BS, Genmin Lu, Pamela B. Conley, PhD, Anne Winkler, MD

Blood (2019) 134 (Supplement_1): 1153.

https://doi.org/10.1182/blood-2019-126254

Published: 2019

Journal Articles

A Pilot Study of an Oral Anticoagulant, Apixaban, in Secondary Prophylaxis of Venous Thromboembolism (VTE) in Children and Adolescents

Ashley Pinchinat, MD, Neida Otero, Harshini Mahanti, BS, MSCR, Erin Morris, RN, BSN, Adele Brudnicki, MD, Deborah Friedman, MD, Simon Li, MD, Oya Levendoglu-Tugal, MD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 2443.

https://doi.org/10.1182/blood-2019-130468

Published: 2019

Journal Articles

Outcomes of Patients Receiving Direct Oral Anticoagulants for Myeloproliferative Neoplasm Associated Venous Thromboembolism

Andrew Doyle, MBBS, BSc, FRPATH, Karen Breen, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, Deepti Radia, Beverley J. Hunt, Gavin Ling, MBBS, BSc, FRCPath, Claire N Harrison, Professor, Natalia Curto Garcia, MD MBBS

Blood (2019) 134 (Supplement_1): 4183.

https://doi.org/10.1182/blood-2019-128170

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The Effect of Anticoagulant Choice on Venous Thromboembolism Recurrence and Bleeding in Sickle Cell Disease

Impact of Adding Aspirin to Direct Oral Anticoagulant Therapy without an Apparent Indication

Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study

High Rates of Venous and Arterial Thrombotic Events in POEMS Patients: Results from the UK-Based POEMS Registry, Highlighting the Need for Therapeutic Guidelines

Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors

Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By Andexanet Alfa and "Work Around" By PCCs

Enhanced VTE Risk Stratification in Ambulatory Patients with Cancer

Bleeding Risk in a Cohort of Ambulatory Cancer Patients Receiving Outpatient Prophylactic Anticoagulation for Venous Thrombosis Prevention

Anticoagulation Challenges in Hematogeriatrics: Effectiveness and Safety of Direct Oral Anticoagulants Vs Vitamin k Antagonist in Elderly with Atrial Fibrillation

Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms

Safety and Efficacy of Apixaban Thromboprophylaxis in Cancer Patients with Metastatic Disease: A Subgroup Analysis of the Avert Trial

Incidental Pulmonary Embolism. Analysis of Mayo Clinic Venous Thromboembolism Database

The Use of Direct Oral Anticoagulants in Non-Cirrhotic Portal Vein Thrombosis

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban By Andexanet Alfa As Measured By Whole Blood Thromboelastographic Analysis

Characterizing the Use of Direct Oral Anticoagulants in Children Using the American Thrombosis and Hemostasis Network Dataset (ATHNdataset)

Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux

Safety and Efficacy of Apixaban Versus Enoxaparin/Warfarin in Patients with Extremes of Body Weight: Post-Hoc Analysis of the AMPLIFY Trial

Modified Anti-FXa Assays for Measuring the Residual Activity of Apixaban and Rivaroxaban in Andexanet Alfa-Containing Samples on the ACL TOP Family ® Coagulation Analyzers

A Pilot Study of an Oral Anticoagulant, Apixaban, in Secondary Prophylaxis of Venous Thromboembolism (VTE) in Children and Adolescents

Outcomes of Patients Receiving Direct Oral Anticoagulants for Myeloproliferative Neoplasm Associated Venous Thromboembolism

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only